ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,011.12
      0.00%
      US Tech 100
      16,935.60
      0.00%
      Dow Jones
      37,775.38
      0.00%
      Brent Oil
      86.145
      -0.31%
      Bitcoin
      65,071.68
      2.46%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. 4D Molecular Therapeutics Inc (FDMT)

      7. 4D Molecular Therapeutics Inc (FDMT) News

      FDMT 4D Molecular Therapeutics Inc

      24.9434
      0.1634 (0.66%)
      Pre Market
      Last Updated: 08:39:11
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      4D Molecular Therapeutics Inc FDMT NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      0.1634 0.66% 24.9434 08:39:11
      Open Price Low Price High Price Close Price Prev Close
      24.78
      more quote information »

      Recent News

      Date Time Source Heading
      3/28/202408:00GLOBE4DMT Announces Update on Regulatory Interactions and..
      3/04/202408:00GLOBE4DMT to Participate in Upcoming Investor Conferences
      2/29/202418:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/29/202417:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
      2/29/202416:12EDGAR2Form 8-K - Current report
      2/29/202416:05GLOBE4DMT Reports Full Year 2023 Financial Results and..
      2/21/202417:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/14/202420:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/14/202416:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/14/202408:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
      2/12/202421:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/12/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/12/202408:00GLOBE4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2..
      2/09/202416:56EDGAR2Form 8-K - Current report
      2/08/202416:50EDGAR2Form 144 - Report of proposed sale of securities
      2/08/202416:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      2/08/202416:22EDGAR2Form 144 - Report of proposed sale of securities
      2/07/202420:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/07/202419:42EDGAR2Form 3/A - Initial statement of beneficial ownership of..
      2/06/202423:27GLOBE4D Molecular Therapeutics Announces Pricing of Upsized..
      2/05/202417:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      2/05/202416:35EDGAR2Form S-3ASR - Automatic shelf registration statement of..
      2/05/202416:05GLOBE4D Molecular Therapeutics Announces Proposed Public Offering..
      2/03/202417:00GLOBE4DMT Presents Positive Interim Data from Randomized Phase 2..
      1/29/202408:00GLOBE4DMT to Host Corporate Webcast to Discuss Interim Data from..
      1/25/202416:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/23/202416:50EDGAR2Form 144 - Report of proposed sale of securities
      1/23/202408:00GLOBE4DMT Receives Rare Pediatric Disease Designation from FDA..
      1/08/202416:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/05/202416:49EDGAR2Form 144 - Report of proposed sale of securities
      1/04/202417:48EDGAR2Form 144 - Report of proposed sale of securities
      1/04/202408:30EDGAR2Form 8-K - Current report
      1/04/202408:00GLOBE4DMT Highlights Recent Clinical Pipeline Progress, Near-Term..
      1/03/202408:01GLOBE4DMT and Arbor Biotechnologies Establish Partnership to..
      12/21/202312:31DJN4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
      12/21/202308:00GLOBE4DMT Receives FDA Regenerative Medicine Advanced Therapy..
      12/18/202317:16EDGAR2Form 144 - Report of proposed sale of securities
      12/15/202317:24EDGAR2Form 144 - Report of proposed sale of securities
      12/13/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/13/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/13/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/13/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/13/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      12/04/202308:00GLOBE4DMT to Present Interim 24 Week Data from Randomized Phase 2..
      11/22/202316:20EDGAR2Form 8-K - Current report
      11/15/202308:00GLOBE4DMT to Participate in Upcoming Investor Conferences
      11/09/202316:23EDGAR2Form 8-K - Current report
      11/09/202316:19GLOBE4DMT Reports Third Quarter 2023 Financial Results and..
      11/01/202316:00GLOBE4DMT Presents Positive Interim Data from Phase 1/2 AEROW..
      10/30/202308:00GLOBE4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold..

      Your Recent History

      NASDAQ
      FDMT
      4D Molecular Therapeutics
      Delayed Upgrade Clock